

Subject Index

- Accelerate Brain Cancer Foundation 234
acetylcholine 173, 186, 244
Addgene 157
adeno-associated viruses 106, 109, 112,
124, 159, 161
affective bias 204, 205
aging 59, 65–69, 80, 85, 87, 95, 103,
129, 156, 180, 222, 225
Allen Institute for Brain Science 19
 α -synuclein 78–80, 95, 100, 103, 238
Alzheimer disease (AD) 77–80, 83, 86,
94, 95, 98, 195, 212
A β 61, 79, 83, 103
biology 64, 69, 70
biomarkers 144, 145
cholinergic hypothesis 219, 243, 244
influence of vascular disease 68–70
modeling 168, 184, 200, 220
neurofibrillary tangles 79, 81, 84, 85,
184, 249
risk for 101, 104, 110
Alzheimer Disease Neuroimaging
Initiative 88, 231
amyloid beta (A β) 61, 62, 78–80, 83, 86,
87, 95, 100, 102
clearance 69, 70
amyloidosis 98, 101, 110, 135
amyloid plaque 69, 79, 85, 168, 184,
220, 249
amyloid precursor protein (APP) 62, 79,
84, 107
human 220
amyotrophic lateral sclerosis (ALS) 21,
63, 65, 80, 94, 95, 170, 225, 249, 251
environmental risk 68
frontotemporal dementia 80, 99
mitochondrial dysfunction 66
modeling 167, 177, 178
TDP-43 61
treating 178
Angelman syndrome 11
Angiopeps 108
animal models 15, 59, 77, 90, 117, 118,
127–131, 213, 217, 240, 248–251.
See also nonhuman primate models,
rodent models
anesthesia effects 133, 135, 136
apoE 105
behavioral 183–208
construct validity 156, 184–186, 198
interface to humans 135, 148–154,
201, 215, 218, 220
limitations 83–86, 162, 167–169, 219,
220
mouse-human brain chimeras 226, 227
neural circuits 121, 122
Parkinsonism 128, 130, 133, 161, 185,
222, 239
tau pathology 100
antibody therapy 74, 89, 107, 212
anxiety 1, 45, 50, 187, 196, 197, 199,
204, 252
apolipoprotein E (apoE) 4, 86, 94, 98,
104, 105, 107, 108, 220
aprotinin 108
Aspiritech 21
associative learning 190, 196–198
attention 18, 97, 188–190, 193, 202, 217
set shifting 195, 196, 202
attention-deficit/hyperactivity disorder
(ADHD) 9, 10, 14, 26, 190–194
CNVs 26
motor impulsivity 202, 203
risk factors 27, 37
synaptic variation 50
AutismKB 13, 14
autism spectrum disorder (ASD) 2,
9–11, 23, 24, 28, 37, 45, 47, 123,
157, 161, 190, 243, 249, 251. *See*
also fragile X syndrome
biology 15–17
CNVs 26, 29, 48
de novo mutations 13, 30, 48
mid-fetal cortical development 17, 155
modeling 162, 178
quality of life 21
risk for 118, 155
social cognition 191, 205

- autism spectrum disorder (continued)
synaptic changes 49–51, 147
- BAC driver lines 157, 158, 161
back-translation 183, 196, 200, 206,
215, 219
bapineuzumab 86, 98
bidirectional approach to research 5,
120, 124, 209, 213–218
bioengineering 181
biofluid assessment 95, 96
biological convergence 33, 34, 53
biomarkers 5, 25, 63, 76, 86–89, 95, 96,
102, 134, 137, 143–148, 222, 232,
248
defined 143, 237
surrogate endpoints 131, 143, 145
biotech industry 3, 54, 210, 228,
231–234, 253
bipolar disorder 1, 23, 24, 26, 29, 34, 43,
191, 212
bistable kinetics 124, 125
blood-brain barrier 4, 69, 70, 94,
103–109, 158, 253
BOLD technique 132, 136, 146, 153
bottom-up approach to research 5, 47,
154, 209–212, 216, 228, 237–239
defined 237
Parkinson disease 238, 239
bradykinesia 71, 101
brain activity marker labeling 123
BRAIN initiative 72
brain stimulation techniques 149, 222
deep brain 72, 101, 130, 133–135, 150,
153, 252
transcranial current (tCS) 149, 157
transcranial magnetic (TMS) 73, 101,
149–153, 157, 222
- Caenorhabditis elegans* 119, 120
calcium imaging 119, 123
calcium sensors 157, 160
Callithrix jacchus 117, 121, 122, 162,
190, 195, 204
CANTAB battery 188–191, 195,
200–202
- cardiovascular disease 1, 36, 87, 93, 94,
100, 251
cell functionality 62, 173, 174
cell replacement 73, 112, 224
cell transplantation 73, 112, 173, 174,
223, 224, 227
cerebral amyloid angiopathy 70, 104
cerebrospinal fluid flow 66, 69, 95, 103
cerebrovascular disease 70, 77
channelrhodopsin 125, 161
CHDI Foundation 234
cholinergic agents 100, 101, 195
cholinergic hypothesis 219, 243, 244
chromatin remodeling 9, 10, 15, 16
chromosomal aneuploidy 11
chronic traumatic encephalopathy 62,
64, 70, 95, 103
CLARITY 117, 122
clinical trials 62, 66, 86, 89, 141–144,
148, 214, 219, 231, 238, 250
candidate selection 21, 81, 88, 95, 98,
134, 178, 188, 237, 248
design 45, 61, 78, 102
failures 60, 178, 247
funding 18, 137
needs 88–90, 112, 217, 236
preclinical studies 85, 86, 90
clozapine 240
CNTRICS process 192
cognition 3, 10, 29, 51, 54, 81, 146
assessing 97, 99, 102, 189, 192–206
impaired 27, 30, 34, 46, 50, 79, 101,
111, 118, 145
modeling 121, 187–206
social 45, 46, 121, 147, 186, 191, 205
collaboration 3, 23, 32, 33, 37, 137, 142,
209, 231–234
comorbidity 9, 20, 25, 27, 87, 99, 100,
188
connectome projects 73, 97, 136, 252
construct validity 156, 184–186, 198
copy number variant (CNV) 11–15, 26,
33–35, 48, 51, 68, 155, 213
impact on cognition 29
CRISPR 2, 119–121, 136, 172
cystic fibrosis 43
cytoskeleton dynamics 9, 16

- data sharing 14, 19, 20, 33, 52, 53, 55
 DATATOP study 81
 Decipher 14
 deep brain stimulation 72, 101, 130,
 133–135, 150, 153, 222, 252
 delayed discounting 203, 205
 delusions 42, 186, 187, 218, 239
 dementia 1, 62, 66, 69, 86, 96, 99, 100,
 248. *See also* Alzheimer disease
 frontotemporal 61–63, 80, 84, 94, 95
 modeling 135, 190, 191, 221
 risk factors 68, 75, 87
 with Lewy bodies 94, 95, 103
de novo mutations 11–14, 26, 30, 48, 50,
 68, 155
 dense neural circuit reconstruction 117,
 123
 deprenyl 81
 depression 1, 43, 45, 121, 146, 184, 186,
 187, 191, 196, 198, 235, 252
 modeling 204
 detection 46–47, 62, 63, 97, 228
 bioethical issues 75, 82, 89
 dexamipexole 178
 diabetes 1, 36, 69, 87, 100
 diagnosis 18, 23–25, 29, 35, 36, 41–43,
 94, 95, 139–143, 229
 biomarkers 63, 86, 87, 131, 137
 new strategies 5, 41, 55, 74
 Diagnostic and Statistical Manual of the
 American Psychiatric Association
 (DSM) 24, 32, 34, 43, 44, 187, 248
 DSM-5 18, 19, 35, 42, 140
 DSM-III 42
 diflunisal 98
 direct current stimulation 150, 152
 direct differentiation 173
 disease burden 1, 59, 60, 77, 78, 93, 94,
 96
 disease classification. *See* nosology
 Dominantly Inherited Alzheimer
 Network 99, 233
 dopamine 73, 86, 185–187, 193, 194
 nigrostriatal pathways 128, 131, 144,
 211
 receptors 31, 34, 129, 161, 240
 Down syndrome 11, 79, 99
Drosophila 19, 119, 120, 136
 drug addiction 46, 190, 191, 196, 197,
 203, 217
 attentional deficits 193
 drug development 141, 183, 209, 224,
 231–233, 236, 237, 240, 252
 delivery 109, 112
 repurposing 83
 dyslexia 10

 early onset neurodevelopmental disor-
 ders 9–22
 electroencephalography (EEG) 71–73,
 133, 149, 150, 153, 217, 248
 electroretinography (ERG) 146, 147,
 149, 157
 embryonic stem cells 119, 170, 172,
 174, 177, 180, 225
 endophenotype 32, 33, 35, 134, 188, 230
 defined 237
 for OCD 196, 204
 environmental assessment technology
 143
 environmental risk 4, 27, 35, 46, 54, 55,
 212, 221
 amyotrophic lateral sclerosis 68
 modeling 162, 185, 226, 242
 Parkinson disease 68, 75
 epigenetics 66, 68, 74, 119, 185, 212,
 213
 epilepsy 17, 26, 27, 67, 72, 101, 149,
 225
 epileptiform activity 67, 68, 84, 101
 episodic memory 162, 188, 201
 ESSENCE 18, 19
 ethical issues 20, 46, 47, 75, 82, 89, 223,
 227
 European Innovative Medicines Initiative
 232, 233
 European Medicines Agency (EMA) 54,
 131, 228, 231, 235
 event-related potentials (ERPs) 133,
 141, 146, 149–152, 157
 evolutionary conservation 30, 214–216,
 218, 219, 221, 249
 executive function 3, 147, 191, 195,
 202–204
 exome sequencing 33, 52, 68, 121

- experimental medicine approach 141,
 216, 228, 229, 236
 extradimensional shifting 196, 204

 fast-to-fail study design 55, 141
 fear 18, 44, 45
 memory 121, 187
 fetal alcohol syndrome 9, 10
 5-choice serial reaction time task
 (5-CSRTT) 190, 194, 195, 203
 Food and Drug Administration (FDA)
 54, 131, 228, 231, 235
 fragile X syndrome 11, 15, 50, 242, 243
 KiTAP test 148
 link to mGluR5 212, 243
 mental retardation protein (FMRP) 16,
 33, 47, 51
 modeling 153, 155
 toxic RNA 65
 frontotemporal dementia (FTD) 61–63,
 80, 84, 94, 95, 99, 221
 inflammation 101
 toxic RNA 65
 future research 31–35, 54, 55, 60, 70,
 72, 106, 109–112, 145–147, 153, 162,
 181, 226, 249, 250

 gadolinium-enhanced lesions 145
 gain-in-function mutations 62, 74
 gamma oscillations 133, 146, 147, 157
 Gene Expression of the Nervous System
 Atlas 158
 gene therapy 73, 112, 253
 genetically encoded voltage sensors 157,
 160
 genetic heterogeneity 31, 48, 51, 117,
 118
 genetic pathoclisia 156, 157
 genetic risk 4, 11, 25, 26, 30, 43, 46, 55,
 75, 101, 104, 110
 genetics 2, 3, 17, 19, 49, 148, 248, 249,
 251
 early onset developmental disorders
 11–15
 impact on nosology 25–29, 35
 genome editing 52, 117–119, 121, 172,
 175, 176
 genome sequencing 12, 52, 96, 110, 121,
 161, 168, 249, 251
 genome-wide association studies
 (GWAS) 14, 26, 31, 33, 51, 53, 110,
 119, 242
 genomics 2, 3, 18, 32, 45, 67, 68, 72, 74,
 90, 120, 175, 178, 181, 252
 gliolymphatic system 106, 109
 gliosis 70, 71, 220
 glymphatic system 69
 goal-directed behavior 157, 197, 217

 habituation 190, 194, 197
 hallucinations 30, 42, 186, 239
 haploinsufficiency 50, 51, 99
 high throughput technologies 2, 49, 52,
 119, 123
 human amyloid precursor proteins
 (hAPPs) 220
 Human Brain Project 140, 142
 Human Connectome Project 97
 Human Genome Project 2, 249
 huntingtin 78, 84, 95, 184
 Huntington disease (HD) 65, 66, 79, 94,
 95, 157, 249, 251
 clinical trials 62, 97
 modeling 129, 184, 190
 Hutchinson–Guilford progeria syndrome
 180
 hypertension 69, 77, 100

 impulsivity 202–204
 induced neuronal cells 223–227
 induced pluripotent stem cells (iPSCs)
 15, 51, 52, 73, 112, 113, 117, 119,
 167–182, 170–175, 209, 213
 use in modeling 178, 223–227
 inflammation 70, 101, 110, 242
 neuro- 105, 106
 innate immune system 4, 94, 101, 109,
 110
 insulin 107, 109, 112
 intellectual disability (ID) 9–11, 16,
 23–26, 50

- de novo* mutations 30
 intellectual property 229, 230, 232
 International Classification of Diseases (ICD) 24, 32, 34–37, 43, 44
 interventional paired-associative stimulation (IPAS) 150–152
 ivacaftor 43

 James Lind Alliance 20

 KiTAP test 148
 Klinefelter syndrome 11

 latent inhibition 190, 194
 L-DOPA 1, 211, 238
 learning 9, 33, 51, 147, 186, 187, 189, 193, 194
 associative 190, 196–198
 goal-directed 196, 197
 impaired 10, 148, 152
 reversal 195, 196, 202, 204, 205, 218, 241
 levetiracetam 101, 220
 levodopa 81, 130, 133
 Lewy bodies 64, 79, 94, 95, 103, 238
 lineage reprogramming 173
 lipid biology 4, 64, 94, 104
 lipoproteins 4, 94, 104, 105
 lithium 1, 21, 51
 long-term memory 50, 198, 200, 201
 loss-of-function (LoF) mutations 12, 26, 34, 52
 low-density lipoprotein receptor (LDLR) 104, 107, 108
 loxapine 179

 magnetoencephalography 71, 72, 133, 217
 mania 42, 45, 193
 marmoset 117, 121, 122, 162, 190, 195, 204
 MATRICS battery 188, 189, 205
 memory 9, 33, 51, 101, 186, 191, 198–202
 episodic 162, 188, 201
 fear 121, 187
 impaired 111, 121, 147, 189, 220, 240, 242
 recognition 191, 199, 200, 206
 reference 191, 200, 201
 semantic 71, 188, 198
 spatial 97, 240, 241
 testing 189, 193, 244
 verbal 147, 191
 working 18, 44, 50, 188, 201, 202, 217
 mGluR5 153, 212, 241, 243
 Michael J. Fox Foundation 229, 234
 microglial activation 15, 109–111
 microRNA 96, 110, 145, 161
 mid-fetal cortical development 17, 155
 mismatched negativity (MMN) 146, 147, 149, 157
 mitochondrial dysfunction 63, 66, 105, 179
 modafinil 196
 modeling 48, 118, 129, 148, 154–163, 175–180, 184–188, 219–227. *See also* animal models
 Alzheimer disease 168, 184, 200, 220
 amyotrophic lateral sclerosis 167, 177, 178
 autism 162, 178
 cognition 121, 187–206
 computer 89, 142
 construct validity 156, 184–186, 198
 dementia 135, 190, 191, 221
 depression 204
 environmental risk 162, 185, 226, 242
 fragile X syndrome 153, 155
 Huntington disease 129, 184, 190
 neural circuits 121, 132–135
 psychiatric disorders 185, 186
 risk genes 157
 schizophrenia 161, 178, 187, 192
 use of iPSCs 223–227
 molecular imaging 72, 95, 96, 131–134
 molecular profiling 211, 226
 Morris water maze 191, 200, 201
 mosaicism 67, 74
 motivation 187, 189, 193, 194, 206

- mouse-human brain chimeras 226, 227
 mRNA translation 9, 16, 65, 73
 multiple sclerosis 2, 78, 88, 94
 biomarkers 145
 myocardial infarction 36. *See also* cardiovascular disease
- NALP3 110, 111
 nanoparticles 106–108, 111
 neural circuits 18, 128, 216, 225
 dysfunction 3, 29, 59, 71, 95–97, 214
 fiber tracking 73
 modeling 121, 132–135
 new analysis methods 72, 122–126
 neurodegeneration 4, 59–61, 64–70, 73, 75, 84, 87, 94, 104–107, 109–111, 184
 neurodegenerative disorders 59–76, 61–68, 93–114, 248
 risk factors 68, 75, 87
 tissue level dysfunction 69–71
 neurodevelopmental disorders 27–30, 41–55, 140, 241, 248
 early onset 9–22
 risk factors 46, 54, 55, 162
 neurofibrillary tangles 79, 81, 84, 85, 184, 249
 neurogenin-2 173
 neuroimaging 32, 43, 88, 97, 130, 132, 133, 201, 215, 217, 218, 252. *See also* positron emission tomography (PET)
 neuroinflammation 105, 106
 neuromuscular disorders 10
 neuroprotection 4, 81, 90, 94, 105, 111–113
 Neuroscience Information Framework 20
 neurotrophic factors 111–113, 152, 224
 neurovascular unit (NVU) 4, 69, 94, 105–109
 new generation sequencing technology 31
 nigrostriatal pathway 128, 131, 144, 211
 nonhuman primate models 83, 90, 125, 136, 221–223
 nigrostriatal neuronal loss 144
 Parkinsonism 130, 133
 social cognition 186, 188, 201
 transgenic 83, 90
 noninvasive techniques 148, 149, 150, 153, 222, 248
 nonpharmacological therapeutics 90, 101, 112, 130, 147. *See also* deep brain stimulation
 omega-3 fatty acids 47
 noradrenaline 186, 203
 nosology 4, 18, 24–26, 34, 35, 140, 187, 248. *See also* DSM, ICD
 current limitations 41–43
 redefining 37, 140, 142
- object recognition 191, 199
 obsessive-compulsive disorder (OCD) 190, 191, 196, 202, 204, 217, 252
 olesoxime 178
 omega-3 fatty acids 47
 oncology 3, 5, 43, 98, 231, 248
 bottom-up approach to research 209, 211, 212
 Online Mendelian Inheritance in Man 14
 opsins 124, 125, 160
 optogenetics 117, 123–125, 153, 154, 157, 158, 160, 222, 252
 animal models 129
- Parkinson disease (PD) 2, 60, 61, 77–81, 86, 94, 95, 100, 144, 145, 180
 animal models 128, 185
 nonhuman primate 130, 133, 222
 rodent 130, 133, 161, 239
 environmental factors 68, 75
 iPSC approach 179–181
 mitochondrial dysfunction 66
 NVU dysfunction 105
 research approach 211, 238, 239
 treatment 81–83, 112, 131, 135. *See also* deep brain stimulation
- patient
 public involvement (PPI) 54
 quality of life 20, 21, 71, 81, 100, 101, 214

- role in research 5, 9, 20, 21, 54, 209, 236
- selection 4, 81, 88, 96, 175, 178, 226, 236
- stratification 3, 23, 32, 37, 44, 45, 93, 98–100, 248
- Patient-Centered Outcomes Research Institute 21
- PatientsLikeMe 21
- perception 188–192
- personalized medicine 21, 36, 45, 142, 167
- pharmaceutical industry 2, 3, 79, 81, 139, 141, 169, 170, 183, 210, 227, 229, 231, 233–237, 253
- pharmacosynthetics 157, 160, 161
- PHAROS study 62, 97
- Phelan-McDermid syndrome 50, 179
- phenotype 19, 49, 52, 169, 210
 - characterization 18, 25, 27, 29, 248
 - complex 34, 35, 37, 48, 53, 156
 - defined 238
 - intermediate 32, 45
 - iPSCs 170, 171, 176
- pleiotropy 23, 25, 26, 32, 37, 48, 139
- polygenicity 117–121, 214, 223
- positron emission tomography (PET) 62, 86, 144, 153, 211
 - amyloid scans 62, 75, 211, 235
 - covariance networks 130
 - FDG 96, 130
 - ligands 74, 97, 141, 248
 - radiopharmaceuticals 235
 - tau scans 62
 - tracer development 74
- postmortem studies 12, 52, 86, 168, 169, 248
 - autism 123
 - Parkinson disease 144, 180
- posttraumatic syndrome disorder (PTSD) 190, 191, 199
- Prader-Willi syndrome 11, 161
- prediction error 187, 192, 218
- PREDICT study 62, 97
- prefrontal cortex (PFC) 121, 122, 162, 186, 195, 222, 240, 241, 249
- prepulse inhibition 190, 193, 242
- prevention 36, 46, 47, 83, 86, 87, 95, 97
 - trials 81, 82, 88, 89, 98
- priming 150, 152
- prodromal stage 46, 47, 82, 188, 200, 201, 211, 240
 - defined 238
- progressive supranuclear palsy 62, 67, 70, 95, 96
- protein aggregation 4, 63, 72, 74, 78, 80, 94–97, 102–104, 179
- protein misfolding 4, 61, 63–65, 70, 74, 78, 94, 106
- proteinopathy 61–67, 96
- proteomics 52, 53, 74, 90, 120
- psychiatric disorders 23, 25, 27, 30, 117–121, 139
 - biomarkers 146, 232, 234
 - complexity 37, 172
 - heritability 31
 - modeling 185, 186
 - treating 197
- psychiatry 25, 37
 - future needs 45, 55, 143, 234, 235
- psychosis 1, 34, 36, 42, 46, 47, 185, 186, 187, 188, 190
 - amphetamine paranoid 239, 240
 - omega-3 fatty acids 37
- public education 20, 54, 55

- quality of life 20, 21, 81, 100, 101, 214

- radioligands 74, 131, 144, 145
- Reactor program 229
- recognition memory 191, 199, 200, 206
- reference memory 191, 200, 201
- regulatory agencies 3, 44, 55, 88, 102, 131, 145, 210, 231, 235, 237
- reparative tissue processes 70, 71
- repetitive transcranial magnetic stimulation (rTMS) 150–152
- Rescorla-Wagner rule 192
- research
 - bidirectional approach 5, 120, 124, 209, 213–218
 - bottom-up approach 5, 47, 154, 209–212, 216, 228, 237–239
 - data sharing 14, 19, 20, 33, 52, 53, 55

- research (continued)
 funding 3, 18, 55, 102, 210, 229, 230, 231, 234, 235, 237
 needs 21, 33, 37, 52. *See also* third space concept
 patient involvement 5, 9, 20, 21, 54, 209, 236
 roadmap 6, 101, 143–148, 249, 250
 statistical robustness 37
 top-down approach 5, 153, 154, 209–211, 213, 228, 238, 239
- Research Domain Criteria (RDoC) 18, 23, 32, 33, 43–45, 140, 141
- Rett syndrome 11, 16, 155, 179
- reversal learning 195, 196, 202, 204, 205, 218, 241
- reward behavior 44, 140, 186, 187, 189
 delayed discounting 203, 205
 impaired 45, 217
- rhesus macaques 121
- rhesus monkeys 195, 205, 222, 240
 risk genes 49, 117–121, 155, 252
 modeling 157
- RNA 65–69, 159
 interference 119, 157, 158
 sequencing 53, 108, 172
- roadmap for future research 6, 101, 143–148, 249, 250. *See also* third space concept
- rodent models 83–85, 123, 157, 163, 183–206, 183–208, 219, 252
 impulsive-compulsive disorders 202
 Parkinsonism 130, 133
 post-training paradigm 198–199
 translation to humans 86, 117, 121, 196, 197, 199, 212
- SAGE labs 21, 162
- schizophrenia 23–27, 29, 34, 42, 50, 118, 155, 190–193, 212, 249, 251
 biomarkers 146
 DA dysfunction 31, 34, 239, 242
de novo mutations 26, 30
 environmental risk 46, 162, 242
 executive function 202
 genetic complexity 30–32, 48, 51, 185
 glutamatergic synapse 51, 240
 MATRICS battery 188, 189, 205
 mid-fetal cortical development 155
 modeling 161, 178, 187, 192
 social cognition 147, 205
 top-down research approach 239–242
- semagacestat trial 79
- semantic memory 71, 188, 198
- sensory tetanization 150, 151
- serotonin 161, 186, 194, 203, 204
- Sestan laboratory 19
- SFARI Gene 13, 14
- SHANK2* 13, 14, 50
- SHANK3* 11, 50, 51, 179
- Simons Foundation 234
- single nucleotide polymorphisms 14, 26, 155, 242
- SMA Foundation 234
- Smith-Magenis syndrome 11
- social cognition 45, 46, 121, 147, 186, 188, 191, 205
- social communication 118, 121
- social isolation 185, 241, 242
- social recognition 199, 206
- spatial memory 97, 240, 241
- Specialisterne 21
- spinal muscular atrophy (SMA) 170, 176, 177, 225
- state marker 232, 238
- stop signal reaction time (SSRT) 202, 203, 218
- substance abuse. *See* drug addiction
- superoxide dismutase-1 (SOD-1) 78, 167, 177
 mouse 84, 178
- synapse formation 9, 16, 17, 67, 172
- synapsopathy 156, 157, 243
- synaptic plasticity 33, 51, 105, 149–152, 243
- synuclein 61, 62, 64, 67, 74, 103
 alpha 78–80, 95, 100, 103, 238
- tafimidis 98
- TALEN 119, 121, 136, 172
- tau 61, 62, 64, 67, 79–81, 95, 100, 103, 145, 221
- TDP-43 61, 64, 78, 80, 95
- theory of mind 186, 191, 205

- therapeutics development 4, 94,
102–104, 147, 157, 212, 226–230,
249, 252, 253
- delivery mechanisms 109, 111–113
- third space concept 5, 209, 218,
228–231, 236
- top-down approach to research 5, 153,
154, 209–211, 213, 228
- defined 238
- Parkinson disease 238, 239
- touch-screen technology 189, 195, 200,
202
- tractable interfaces 5, 139, 148–154, 157
- trait markers 232, 238
- transcranial current stimulation (tCS)
149, 157
- transcranial magnetic stimulation (TMS)
73, 101, 149, 153, 157, 222
- paired-pulse 150
- repetitive 150–152
- transdifferentiation 173
- transferrin receptor 107, 108
- transgenic mice 19, 84, 85, 129, 177,
220, 226, 239
- Shank3 50, 51
- transgenic models 73, 107, 221
- nonhuman primates 83, 90
- translational science 227–236
- Reactor program 229
- research-clinical divide 234, 235
- trisomy 21 11, 79, 99
- Turner syndrome 11
- valproate 51
- vascular disease 68–70, 77, 87, 94, 100
- velocardiofacial syndrome 11, 155
- venture capital groups 228, 231, 233
- verbal memory 147, 191
- vertigo 197
- vigilance 190, 193, 194
- viral-mediated gene targeting 180
- viral transfection 74, 106, 111, 158, 161
- Wechsler Adult IQ Scale (WAIS) 188,
189
- white matter atrophy 69, 73
- Wisconsin Card Sorting Test 190, 195,
196, 217
- working memory 18, 44, 188, 191, 198,
201, 202, 217, 241
- enhanced 50
- impaired 121, 240, 242
- zebrafish 119, 120, 135, 136

Further Titles in the Strüngmann Forum Report Series¹

Better Than Conscious?

Decision Making, the Human Mind, and Implications For Institutions
edited by Christoph Engel and Wolf Singer, ISBN 978-0-262-19580-5

Clouds in the Perturbed Climate System:

Their Relationship to Energy Balance, Atmospheric Dynamics, and Precipitation
edited by Jost Heintzenberg and Robert J. Charlson, ISBN 978-0-262-01287-4

Biological Foundations and Origin of Syntax

edited by Derek Bickerton and Eörs Szathmáry, ISBN 978-0-262-01356-7

Linkages of Sustainability

edited by Thomas E. Graedel and Ester van der Voet, ISBN 978-0-262-01358-1

Dynamic Coordination in the Brain: From Neurons to Mind

edited by Christoph von der Malsburg, William A. Phillips and Wolf Singer,
ISBN 978-0-262-01471-7

Disease Eradication in the 21st Century: Implications for Global Health

edited by Stephen L. Cochi and Walter R. Dowdle, ISBN 978-0-262-01673-5

Animal Thinking: Contemporary Issues in Comparative Cognition

edited by Randolph Menzel and Julia Fischer, ISBN 978-0-262-01663-6

Cognitive Search: Evolution, Algorithms, and the Brain

edited by Peter M. Todd, Thomas T. Hills and Trevor W. Robbins,
ISBN 978-0-262-01809-8

Evolution and the Mechanisms of Decision Making

edited by Peter Hammerstein and Jeffrey R. Stevens, ISBN 978-0-262-01808-1

Language, Music, and the Brain: A Mysterious Relationship

edited by Michael A. Arbib, ISBN 978-0-262-01962-0

Cultural Evolution: Society, Technology, Language, and Religion

edited by Peter J. Richerson and Morten H. Christiansen,
ISBN 978-0-262-01975-0

Schizophrenia: Evolution and Synthesis

edited by Steven M. Silverstein, Bitá Moghaddam and Til Wykes,
ISBN 978-0-262-01962-0

Rethinking Global Land Use in an Urban Era

edited by Karen C. Seto and Anette Reenberg, ISBN 978-0-262-02690-1

Trace Metals and Infectious Diseases

edited by Jerome O. Nriagu and Eric P. Skaar, ISBN 978-0-262-02919-3

¹ available at <https://mitpress.mit.edu/books/series/str%C3%BCngmann-forum-reports-0>

